Answers are grounded in this paper and cite their sources.
Introduction The widespread adoption of AI and synthetic biology is creating value while also bringing bio-risk management challenges into sharper focus. Risk mitigation is commonly divided into biosafety, which aims to prevent exposure to or release of biological agents, and biosecurity, which aims to deter theft, diversion, and misuse. In recent years, the scope of biosecurity has expanded to include pandemic prevention and the governance of dual-use technologies. DNA synthesis, which converts digital sequence information into physical molecules, serves as a critical gateway for managing misuse potential. Consequently, sequence screening upon order acceptance and customer screening have become key focal points for risk management. Methods To assess the current status of biosecurity awareness and implementation among organizations involved in ordering synthetic DNA in Japan, we conducted an anonymous web-based survey of member organizations of the Japan Bioindustry Association across four domains (regulatory and institutional frameworks, risk awareness, social responsibility, and sequence screening) and analyzed responses from 107 organizations. Results While overall awareness was high, the development of internal misuse-prevention policies and the establishment of criteria and standard operating procedures (SOPs) for sequence-screening determinations lagged behind. In particular, sequence screening showed a pronounced gap between recognition of its importance and procedural preparedness. Discussion These findings underscore the importance of developing and disseminating practical, up-to-date, and implementable guidance to support the transition from awareness to operational readiness.
No takes yet. Share an insight, caveat, or question.
Kentaro Hayashi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: